Table 1 Baseline clinical and diagnostic biopsy pathologic variables of the cohort
Cohort characteristics | ||||
|---|---|---|---|---|
All patients (N = 119) | Triple negative (N = 32) | ER-positive (N = 41) | HER2+ (N = 46) | |
Follow-Up, Median (Years) [Range] | 4.7 [0.6–7.7] | 4.4 [0.6–7.0] | 4.3 [0.9–7.7] | 4.8 [2.1–7.0] |
Age, Median (Range) | 49 (24–79) | 50 (24–70) | 48 (32–77) | 50 (33–79) |
Sex, n (%) | ||||
F | 118 (99.2%) | 32 (100.0%) | 40 (97.6%) | 46 (100.0%) |
M | 1 (0.8%) | 0 (0.0%) | 1 (2.4%) | 0 (0.0%) |
Menopausal status, n (%) | ||||
Post | 42 (35.6%) | 12 (37.5%) | 11 (27.5%) | 19 (41.3%) |
Pre | 76 (64.4%) | 20 (62.5%) | 29 (72.5%) | 27 (58.7%) |
Missing | 1 | 0 | 1 | 0 |
Tumour Size, n (%) | ||||
T1/T2 | 79 (66.4%) | 25 (78.1%) | 20 (48.8%) | 34 (73.9%) |
T3/T4 | 40 (33.6%) | 7 (21.9%) | 21 (51.2%) | 12 (26.1%) |
Nodal Status, n (%) | ||||
N0 | 46 (38.7%) | 19 (59.4%) | 16 (39.0%) | 11 (23.9%) |
N1 | 73 (61.3%) | 13 (40.6%) | 25 (61.0%) | 35 (76.1%) |
Grade (Diagnostic biopsy), n (%) | ||||
2 | 32 (26.9%) | 2 (6.3%) | 19 (46.3%) | 11 (23.9%) |
2 to 3 | 24 (20.2%) | 6 (18.8%) | 7 (17.1%) | 11 (23.9%) |
3 | 63 (52.9%) | 24 (75.0%) | 15 (36.6%) | 24 (52.2%) |
Histology, n (%) | ||||
IDC | 110 (92.4%) | 29 (90.6%) | 37 (90.2%) | 44 (95.7%) |
Other | 9 (7.6%) | 3 (9.4%) | 4 (9.8%) | 2 (4.3%) |
Neoadjuvant treatment, n (%) | ||||
Anthracycline + Taxane | 103 (86.6%) | 28 (87.5%) | 39 (95.1%) | 36 (78.3%) |
Endocrine Therapy | 2 (1.7%) | 0 (0.0%) | 2 (4.9%) | 0 (0.0%) |
Taxane | 14 (11.8%) | 4 (12.5%) | 0 (0.0%) | 10 (21.7%) |
Pathological outcome, n (%) | ||||
RCB-0 | 34 (28.6%) | 9 (28.1%) | 4 (9.8%) | 21 (45.7%) |
RCB-1 | 25 (21.0%) | 8 (25.0%) | 3 (7.3%) | 14 (30.4%) |
RCB-2 | 43 (36.1%) | 11 (34.4%) | 23 (56.1%) | 9 (19.6%) |
RCB-3 | 17 (14.3%) | 4 (12.5%) | 11 (26.8%) | 2 (4.3%) |
Recurrences, n (%) | ||||
No | 100 (84.0%) | 25 (78.1%) | 30 (73.2%) | 45 (97.8%) |
Yes | 19 (16.0%) | 7 (21.9%) | 11 (26.8%) | 1 (2.2%) |
